Companies › Oligomerix
1 active drug program in 1 registered trial: 1 Phase 1; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OLX-07010 tau self-association inhibitor | MAPT | Phase 1 | Alzheimer Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05696483 | OLX-07010 | Phase 1 | Alzheimer Disease | Neurology | May 2026 |
Eli Radiopharma Bristol-Myers Squibb Roche Voyager Therapeutics Amyloid Solution Arrowhead Pharmaceuticals Nuravax UCB Biopharma SRL
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.